Related Experiment Video
Updated: May 30, 2026
07:50
Efficient Agroinfiltration of Plants for High-level Transient Expression of Recombinant Proteins
Published on: July 23, 2013
GMP issues for recombinant plant-derived pharmaceutical proteins.
Rainer Fischer1, Stefan Schillberg, Stephan Hellwig
1Fraunhofer Institute for Molecular Biology and Applied Ecology (IME), Aachen, Germany. rainer.fischer@molbiotech.rwth-aachen.de
Biotechnology Advances
|August 23, 2011
Summary
Producing plant-derived pharmaceutical proteins (PDPs) requires adherence to Good Manufacturing Practice (GMP) regulations. While plant cell bioreactors align with GMP, whole-plant systems need regulatory adaptation for clinical development.
Area of Science:
- Biotechnology
- Pharmaceutical Manufacturing
- Plant Molecular Biology
Background:
- Recombinant proteins for medical use, known as plant-derived pharmaceutical proteins (PDPs), can be produced in various plant systems, from whole plants to cell cultures in bioreactors.
- The manufacturing of PDPs intended for clinical use must comply with Good Manufacturing Practice (GMP) regulations, similar to pharmaceuticals from other sources.
Purpose of the Study:
- To evaluate the applicability of existing Good Manufacturing Practice (GMP) regulations to plant-based production systems for pharmaceuticals.
- To identify challenges and necessary adaptations for GMP compliance in different plant production platforms.
Main Methods:
- Review of existing GMP guidelines for pharmaceutical protein production in microbial and mammalian systems.
- Analysis of plant-based production systems, including whole plants and plant cell suspension cultures in bioreactors, concerning GMP requirements.
- Assessment of regulatory challenges for adapting GMP to plant-specific production environments.
Main Results:
- Plant cell cultures in bioreactors offer a contained, sterile environment that more readily meets current GMP criteria.
- Whole-plant production systems require significant modifications to existing GMP regulations for compliance.
- Recent advancements have enabled the development of the first GMP-compliant production processes using whole-plant systems.
Conclusions:
- Adapting GMP regulations is crucial for the successful clinical development of plant-derived pharmaceutical proteins.
- Plant cell bioreactors present a more straightforward path to GMP compliance compared to whole-plant systems.
- Continued innovation is necessary to fully integrate whole-plant systems into GMP-compliant pharmaceutical manufacturing.
Related Concept Videos
01:27Upstream Processing
Upstream processing represents a critical phase in biomanufacturing, wherein biological systems such as microorganisms, mammalian cells, or insect cells are cultivated to produce therapeutic proteins, vaccines, enzymes, or other biologically derived products. This phase encompasses all steps from the selection and genetic manipulation of the production organism to the cultivation of cells in bioreactors under tightly controlled environmental conditions.Host Selection and Genetic OptimizationThe...
01:30Production of Pharmaceuticals
Industrial insulin production uses genetically engineered E. coli expressing a proinsulin gene controlled by a tryptophan promoter and containing a methionine linker for later cleavage. The cells also carry ampicillin resistance for selective growth. Seed cultures are stored at −80 °C and production begins by thawing a small amount to inoculate starter cultures, which are progressively scaled to a 50,000-L bioreactor. In the bioreactor, E. coli grow in nutrient-rich media under sterile, tightly...
01:09Recombinant DNA
Overview
01:26Good Manufacturing Practices
Good Manufacturing Practices (GMP) constitute a foundational set of guidelines that ensure the production of safe, consistent, and high-quality products, particularly in industries such as pharmaceuticals, biotechnology, and food processing. These protocols encompass all aspects of production, from the sourcing of raw materials to the final distribution of the finished product.A core pillar of GMP is stringent hygiene and sanitation across all production environments. This includes routine...
02:50Transgenic Plants
Recombinant DNA technology called transgenesis is often used to add a foreign gene or remove a detrimental gene from an organism. Such genetically modified organisms are called transgenic organisms.
The first-ever transgenic plant was a tobacco plant developed in 1983 that showed resistance against the tobacco mosaic virus. Since then, many transgenic plants have been developed and commercialized for improving the agricultural, ornamental, and horticultural value of a crop plant. Transgenic...
The first-ever transgenic plant was a tobacco plant developed in 1983 that showed resistance against the tobacco mosaic virus. Since then, many transgenic plants have been developed and commercialized for improving the agricultural, ornamental, and horticultural value of a crop plant. Transgenic...
01:19Pharmaceutical Alternatives: Excipients and Impurities-Related Therapeutic Nonequivalence
Pharmaceutical products contain more than just the active drug; they also contain various excipients such as binders, solubilizers, stabilizers, preservatives, and other elements. In some cases, impurities or contaminants might be present. Traditionally, quality control in pharmaceuticals has primarily focused on the analysis of the active drug, often overlooking the impact of these additional components. The recent issue with heparin contamination by over-sulfated chondroitin sulfate, a...